-
公开(公告)号:US20110060009A1
公开(公告)日:2011-03-10
申请号:US12870186
申请日:2010-08-27
申请人: Clinton A. BROOKS , Christine Hiu-Tung CHEN , Young Shin CHO , Lei JIANG , Gang LIU , Michael SHULTZ
发明人: Clinton A. BROOKS , Christine Hiu-Tung CHEN , Young Shin CHO , Lei JIANG , Gang LIU , Michael SHULTZ
IPC分类号: A61K31/4439 , C07D403/06 , A61K31/4045 , C07D401/06 , C07D401/14 , A61K31/4155 , A61K31/4192 , A61P35/00 , A61P25/28 , A61P25/16 , A61P9/00 , A61P19/02 , C12N9/99
CPC分类号: C07D403/06 , C07D401/14 , C07D403/04 , C07D498/06
摘要: The present teachings relate to compounds of Formula I: and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, R4, R5, ring A, and Z are as defined herein.The present teachings also provide methods of preparing compounds of Formula I and methods of use compounds of Formula I in treating pathologic conditions or disorders mediated wholly or in part by deacetylases.
摘要翻译: 本发明涉及式I化合物及其药学上可接受的盐,水合物,酯和前药,其中R 1,R 2,R 3,R 4,R 5,环A和Z如本文所定义。 本教导还提供制备式I化合物的方法和使用式I化合物治疗全部或部分由脱乙酰酶介导的病理状况或病症的方法。
-
公开(公告)号:US20170183352A1
公开(公告)日:2017-06-29
申请号:US15231005
申请日:2016-08-08
申请人: Gilbert BESONG , Christopher Thomas BRAIN , Clinton A. BROOKS , Miles Stuart CONGREVE , Claudio DAGOSTIN , Guo HE , Ying HOU , Steven HOWARD , Yue LI , Yipin LU , Paul MORTENSON , Troy SMITH , Moo Je SUNG , Steven WOODHEAD , Wojciech WRONA , Bharat LAGU
发明人: Gilbert BESONG , Christopher Thomas BRAIN , Clinton A. BROOKS , Miles Stuart CONGREVE , Claudio DAGOSTIN , Guo HE , Ying HOU , Steven HOWARD , Yue LI , Yipin LU , Paul MORTENSON , Troy SMITH , Moo Je SUNG , Steven WOODHEAD , Wojciech WRONA , Bharat LAGU
IPC分类号: C07D487/04 , A61K31/519
CPC分类号: C07D487/04 , A61K31/519 , C07D487/08
摘要: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
-